Analyst Viewpoint
Growth in prevalence of thalassemia and R&D of new drugs for thalassemia treatment are driving the global thalassemia treatment market size. Various drugs for the treatment of thalassemia are in the pipeline. The majority of them are undergoing trials between Phase I and III.
Stem cell therapy is gaining traction for the treatment of thalassemia, especially for severe cases. Gene-edited cell therapy is also gaining popularity for the treatment of transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older.
Players in the thalassemia treatment market landscape are broadening their focus toward the treatment of alpha-thalassemia and beta-thalassemia. They are developing advanced thalassemia treatment strategies to expand their product portfolio.
Thalassemia is one of the inherited blood disorders in which the body produces an inadequate quantity of hemoglobin. Blood transfusion solutions and chelation therapy are among the common treatments.
Chelation therapy makes use of drugs, such as deferasirox, for the treatment of chronic iron overloads that occur during frequent blood transfusions amongst non-transfusion-dependent thalassemia patients. They are administered subcutaneously or intravenously with slow infusion to purify the blood.
High treatment costs may compel the population in under-developed economies to give a second thought about resorting to thalassemia treatment. This factor may restrain the thalassemia treatment market development.
According to Boston Children’s Hospital, nearly 300 million individuals across the globe suffer from thalassemia trait. These individuals are at a higher risk of begetting children with thalassemia. The hospital further states that more than 100 thousand people are diagnosed with transfusion-dependent thalassemia.
Fetal hemoglobin inducers are recommended, such that decitabine and hydroxyurea can be successfully induced to elevate levels of fetal hemoglobin. Rise in need to reduce the number of thalassemia-infected patients (to prevent children from getting affected) is prompting extensive research pertaining to thalassemia treatment.
This, in turn, is augmenting the thalassemia treatment market demand. Various studies are focusing on devising erythropoiesis-stimulating agents to treat millions of adults contracting thalassemia due to kidney failure.
Beta-thalassemia is prevalent in the Middle East, Mediterranean, South Asia, Africa, and India. It is conventionally managed through red blood cell transfusions at periodic intervals, usually every two to four weeks, followed by chelation therapy with deferoxamine (Novartis; Desferal) or deferasirox for removing excess iron from the bloodstream.
Patients, without these two courses of action, are likely to experience symptoms such as liver and cardiac ailments or chronic fatigue.
Emerging treatments like gene therapy aim to address the genetic mutations causing thalassemia. Gene therapy for thalassemia is still under research and development. Stem cell therapy, particularly hematopoietic stem cell transplantation (HSCT), is one of the primary and potentially curative treatments for thalassemia, especially for severe cases.
In 2019, the U.S. FDA approved luspatrcept-aamt (Reblozyl) for the treatment of thalassemia. Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia.
R&D of stem cell-based gene therapies is driving the thalassemia treatment market share. In 2019, Vifor Pharma reported positive phase-I trial results for its oral ferroportin inhibitor. In all treated trial participants, the ferroportin inhibitor was well tolerated with mild to moderate side effects that were transient and self-limiting.
According to the latest thalassemia treatment market forecast, North America is expected to hold largest share from 2023 to 2031. The region accounted for major share in 2022. Rise in awareness regarding thalassemia coupled with governments rendering support to gene therapy is fueling the market dynamics of the region.
The thalassemia treatment market growth in Europe and Asia Pacific can be ascribed to high demand for gene therapy for thalassemia treatment and surge in investment in healthcare infrastructure.
Increase in awareness regarding thalassemia is also boosting the market statistics in these regions. Healthcare experts state that marriages amongst cousins are likely to cause thalassemia in the progeny, especially in Asia Pacific.
Key players are engaging in extensive R&D activities to expand their product portfolio. Bluebird Bio, Inc., Merck & Co., Inc., Novartis AG, Celgene Corporation, Takeda Pharmaceutical Company Limited, Incyte Corporation, Sanofi, Bellicum Pharmaceuticals, and GSK plc are some of the key players in the thalassemia treatment industry.
Each of these companies has been profiled in the thalassemia treatment market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 791.8 Mn |
| Market Forecast (Value) in 2031 | US$ 1.5 Bn |
| Growth Rate (CAGR) | 7.3% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Mn/Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 791.8 Mn in 2022
It is projected to grow at a CAGR of 7.3% from 2023 to 2031
Growth in prevalence of thalassemia and R&D of new drugs for thalassemia treatment
The chelation therapy segment accounted for the largest share in 2022
North America was the dominant region in thalassemia treatment market in 2022
Bluebird Bio, Inc., Merck & Co., Inc., Novartis AG, Celgene Corporation, Takeda Pharmaceutical Company Limited, Incyte Corporation, Sanofi, Bellicum Pharmaceuticals, and GSK plc
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Thalassemia Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Thalassemia Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Thalassemia Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Blood Transfusion
6.3.2. Chelation Therapy
6.3.3. Bone Marrow Transplantation
6.3.4. Others
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Thalassemia Treatment Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region, 2017–2031
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Region
8. North America Thalassemia Treatment Market Analysis and Forecast
8.1. Introduction
8.2. Key Findings
8.3. Market Value Forecast, by Treatment Type, 2017–2031
8.3.1. Blood Transfusion
8.3.2. Chelation Therapy
8.3.3. Bone Marrow Transplantation
8.3.4. Others
8.4. Market Value Forecast, by Country, 2017–2031
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Treatment Type
8.5.2. By Country
9. Europe Thalassemia Treatment Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Treatment Type, 2017–2031
9.3.1. Blood Transfusion
9.3.2. Chelation Therapy
9.3.3. Bone Marrow Transplantation
9.3.4. Others
9.4. Market Value Forecast, by Country/Sub-region, 2017–2031
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Treatment Type
9.5.2. By Country/Sub-region
10. Asia Pacific Thalassemia Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2017–2031
10.3.1. Blood Transfusion
10.3.2. Chelation Therapy
10.3.3. Bone Marrow Transplantation
10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Treatment Type
10.5.2. By Country/Sub-region
11. Latin America Thalassemia Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2017–2031
11.3.1. Blood Transfusion
11.3.2. Chelation Therapy
11.3.3. Bone Marrow Transplantation
11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Market Attractiveness Analysis
11.5.1. By Treatment Type
11.5.2. By Country/Sub-region
12. Middle East & Africa Thalassemia Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2017–2031
12.3.1. Blood Transfusion
12.3.2. Chelation Therapy
12.3.3. Bone Marrow Transplantation
12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of Middle East & Africa
12.5. Market Attractiveness Analysis
12.5.1. By Treatment Type
12.5.2. By Country/Sub-region
13. Competition Landscape
13.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
13.2. Market Share Analysis, by Company (2022)
13.3. Company Profiles
13.3.1. Bluebird Bio, Inc.
13.3.1.1. Company Overview
13.3.1.2. Product Portfolio
13.3.1.3. SWOT Analysis
13.3.1.4. Financial Overview
13.3.1.5. Strategic Overview
13.3.2. Merck & Co., Inc.
13.3.2.1. Company Overview
13.3.2.2. Product Portfolio
13.3.2.3. SWOT Analysis
13.3.2.4. Financial Overview
13.3.2.5. Strategic Overview
13.3.3. Novartis AG
13.3.3.1. Company Overview
13.3.3.2. Product Portfolio
13.3.3.3. SWOT Analysis
13.3.3.4. Financial Overview
13.3.3.5. Strategic Overview
13.3.4. Celgene Corporation
13.3.4.1. Company Overview
13.3.4.2. Product Portfolio
13.3.4.3. SWOT Analysis
13.3.4.4. Financial Overview
13.3.4.5. Strategic Overview
13.3.5. Takeda Pharmaceuticals Company Limited
13.3.5.1. Company Overview
13.3.5.2. Product Portfolio
13.3.5.3. SWOT Analysis
13.3.5.4. Financial Overview
13.3.5.5. Strategic Overview
13.3.6. Incyte Corporation
13.3.6.1. Company Overview
13.3.6.2. Product Portfolio
13.3.6.3. SWOT Analysis
13.3.6.4. Financial Overview
13.3.6.5. Strategic Overview
13.3.7. Sanofi
13.3.7.1. Company Overview
13.3.7.2. Product Portfolio
13.3.7.3. SWOT Analysis
13.3.7.4. Financial Overview
13.3.7.5. Strategic Overview
13.3.8. Bellicum Pharmaceuticals
13.3.8.1. Company Overview
13.3.8.2. Product Portfolio
13.3.8.3. SWOT Analysis
13.3.8.4. Financial Overview
13.3.8.5. Strategic Overview
13.3.9. GSK plc
13.3.9.1. Company Overview
13.3.9.2. Product Portfolio
13.3.9.3. SWOT Analysis
13.3.9.4. Financial Overview
13.3.9.5. Strategic Overview
List of Tables
Table 01: Global Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 02: Global Thalassemia Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 03: North America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 04: North America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 05: Europe Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 06: Europe Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 07: Asia Pacific Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: Asia Pacific Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 09: Latin America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Latin America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
Table 11: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031
List of Figures
Figure 01: Global Thalassemia Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Thalassemia Treatment Market Revenue (US$ Mn), by Treatment Type, 2022
Figure 03: Global Thalassemia Treatment Market Value Share, by Treatment Type, 2022
Figure 04: Global Thalassemia Treatment Market Value Share, by Region, 2022
Figure 05: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, 2023–2031
Figure 06: Global Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031
Figure 07: Global Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 08: Global Thalassemia Treatment Market Value Share Analysis, by Region, 2022–2031
Figure 09: Global Thalassemia Treatment Market Attractiveness Analysis, by Region, 2023–2031
Figure 10: North America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 11: North America Thalassemia Treatment Market Attractiveness Analysis, by Country, 2023–2031
Figure 12: North America Thalassemia Treatment Market Value Share Analysis, by Country, 2022–2031
Figure 13: North America Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031
Figure 14: North America Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 15: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 16: Europe Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 17: Europe Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 18: Europe Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031
Figure 19: Europe Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 20: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 21: Asia Pacific Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 22: Asia Pacific Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 23: Asia Pacific Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031
Figure 24: Asia Pacific Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 25: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 26: Latin America Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 27: Latin America Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 28: Latin America Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031
Figure 29: Latin America Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 30: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 31: Middle East & Africa Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 32: Middle East & Africa Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 33: Middle East & Africa Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031
Figure 34: Middle East & Africa Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Thalassemia Treatment Market
